Mondego Bio

Portugal
Cantanhede, Coimbra, Portugal

Company profile

Mondego Bio company profile

Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees

Headquarters

Country code
PT
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Last funding
Series A / 2025-09-18
Last equity funding
Series A
Investors
3
Lead investors
1
Articles
8

Founders and investors

Lead investors

Biovance Capital

Investors

Biovance CapitalOrbiMedTorrey Pines Investment